Discovery and Characterization of SNX27: A Potential Drug Target Or Biomarker

Discovery and Characterization of SNX27: A Potential Drug Target Or Biomarker

SNX27 (KIAA0488) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of theSnx family of proteins, which are known for their role in intracellular signaling. SNX27 has been shown to play a role in a variety of physiological processes, including cell survival, proliferation, and differentiation. As a result, SNX27 has potential as a drug target or biomarker.

The discovery and characterization of SNX27 was made by a research team led by Dr. Xinran Li, a Professor of Molecular Biology and Biochemistry at the University of California, Los Angeles (UCLA). Dr. Li's team identified SNX27 as a protein that was expressed in the brain and was involved in the regulation of cell survival and proliferation. They also showed that SNX27 was involved in the regulation of cellular processes such as cell migration and the formation of blood vessels.

The potential drug target status of SNX27 is based on its involvement in cell survival and proliferation. SNX27 has been shown to play a role in the regulation of cell survival by promoting the production of a protein called Bcl-2. This protein helps to protect cells from the effects of stress and can lead to cell death. By promoting the production of Bcl-2, SNX27 may be able to contribute to the development of cancer.

In addition to its potential role in cancer, SNX27 may also be a useful biomarker for the diagnosis and prognosis of other diseases. For example, SNX27 has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancer . This suggests that it may be a useful diagnostic or prognostic marker for these diseases. Additionally, the levels of SNX27 have been shown to be associated with the severity of certain diseases, such as heart failure and neurodegenerative diseases. This may make SNX27 a useful target for therapies aimed at these conditions.

The potential drug targeting of SNX27 is an exciting area of 鈥嬧?媟esearch, and further studies are needed to fully understand its potential. Dr. Li's team is currently working on developing small molecules that can inhibit the activity of SNX27 and are investigating the potential efficacy of these drugs in preclinical studies. They are also exploring the use of SNX27 as a biomarker for the diagnosis and prognosis of cancer.

In conclusion, SNX27 is a protein that has been shown to play a role in a variety of physiological processes and is expressed in various tissues of the body. Its potential as a drug target or biomarker is based on its involvement in cell survival and proliferation. Further studies are needed to fully understand its potential and to explore its use as a therapeutic agent.

Protein Name: Sorting Nexin 27

Functions: Involved in the retrograde transport from endosome to plasma membrane, a trafficking pathway that promotes the recycling of internalized transmembrane proteins. Following internalization, endocytosed transmembrane proteins are delivered to early endosomes and recycled to the plasma membrane instead of being degraded in lysosomes. SNX27 specifically binds and directs sorting of a subset of transmembrane proteins containing a PDZ-binding motif at the C-terminus: following interaction with target transmembrane proteins, associates with the retromer complex, preventing entry into the lysosomal pathway, and promotes retromer-tubule based plasma membrane recycling. SNX27 also binds with the WASH complex. Interacts with membranes containing phosphatidylinositol-3-phosphate (PtdIns(3P)). May participate in establishment of natural killer cell polarity. Recruits CYTIP to early endosomes

The "SNX27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140 | SP140L | SP2 | SP2-AS1 | SP3